Select therapeutic use:

Bladder, kidney, and other urologic cancers:

Indications for MVASI:

Metastatic renal cell carcinoma (mRCC) in combination with interferon alfa.

Adult:

Give by IV infusion. Infuse 1st dose over 90mins; if tolerated, infuse 2nd dose over 60mins, and subsequent doses over 30mins. 10mg/kg every 2 weeks with interferon alfa until disease progression or unacceptable toxicity.

Children:

<18yrs: not established.

Warnings/Precautions:

Do not start therapy before or for at least 28 days after surgery; allow surgical incisions to completely heal (see full labeling). Do not administer if recent history of hemoptysis of ≥ ½-teaspoon of red blood. Discontinue if GI perforations, tracheoesophageal fistula, grade 4 fistula, or fistula formation involving any organ. Discontinue if wound healing complications, Grade 3 or 4 hemorrhage, severe arterial thromboembolic event, grade 4 venous thromboembolic event, hypertensive crisis or encephalopathy, posterior reversible encephalopathy syndrome (PRES), nephrotic syndrome, severe infusion-related reactions, or CHF develops; withhold if severe hypertension or proteinuria ≥2g/24hrs (resume when <2g/24hrs) occurs. History of arterial thromboembolism. Diabetes. Monitor BP every 2–3 weeks. Monitor proteinuria by dipstick urine analysis; if ≥2+, do further assessment with a 24-hour urine collection. Elderly. Increased risk of ovarian failure (premenopausal women). Embryo-fetal toxicity. Advise females of reproductive potential to use effective contraception during and for 6 months after last dose. Pregnancy. Nursing mothers: not recommended (during and for 6 months after last dose).

Pharmacologic Class:

Vascular endothelial growth factor (VEGF) inhibitor.

Interactions:

Increased risk of CHF and decline in LVEF with concomitant anthracycline-based therapy (not indicated use).

Adverse Reactions:

Epistaxis, headache, hypertension, rhinitis, proteinuria, taste alteration, dry skin, rectal hemorrhage, lacrimation disorder, back pain, exfoliative dermatitis; GI perforation and fistulae, wound dehiscence/impaired healing, necrotizing fasciitis (discontinue if occurs), hemorrhage, non-GI fistula formation, arterial or venous thromboembolic events, PRES, infusion-related reactions, ovarian failure, neutropenia, infection.

Generic Availability:

NO

How Supplied:

Single-dose vial (4mL, 16mL)—1

Pricing for MVASI

16ml of 400mg/16ml vial (Qty: 1)
Appx. price $2690
GoodRx

CNS cancers:

Indications for MVASI:

Recurrent gliobastoma in adults.

Adult:

Give by IV infusion. Infuse 1st dose over 90mins; if tolerated, infuse 2nd dose over 60mins, and subsequent doses over 30mins. 10mg/kg every 2 weeks.

Children:

<18yrs: not established.

Warnings/Precautions:

Do not start therapy before or for at least 28 days after surgery; allow surgical incisions to completely heal (see full labeling). Do not administer if recent history of hemoptysis of ≥ ½-teaspoon of red blood. Discontinue if GI perforations, tracheoesophageal fistula, grade 4 fistula, or fistula formation involving any organ. Discontinue if wound healing complications, Grade 3 or 4 hemorrhage, severe arterial thromboembolic event, grade 4 venous thromboembolic event, hypertensive crisis or encephalopathy, posterior reversible encephalopathy syndrome (PRES), nephrotic syndrome, severe infusion-related reactions, or CHF develops; withhold if severe hypertension or proteinuria ≥2g/24hrs (resume when <2g/24hrs) occurs. History of arterial thromboembolism. Diabetes. Monitor BP every 2–3 weeks. Monitor proteinuria by dipstick urine analysis; if ≥2+, do further assessment with a 24-hour urine collection. Elderly. Increased risk of ovarian failure (premenopausal women). Embryo-fetal toxicity. Advise females of reproductive potential to use effective contraception during and for 6 months after last dose. Pregnancy. Nursing mothers: not recommended (during and for 6 months after last dose).

Pharmacologic Class:

Vascular endothelial growth factor (VEGF) inhibitor.

Interactions:

Increased risk of CHF and decline in LVEF with concomitant anthracycline-based therapy (not indicated use).

Adverse Reactions:

Epistaxis, headache, hypertension, rhinitis, proteinuria, taste alteration, dry skin, rectal hemorrhage, lacrimation disorder, back pain, exfoliative dermatitis; GI perforation and fistulae, wound dehiscence/impaired healing, necrotizing fasciitis (discontinue if occurs), hemorrhage, non-GI fistula formation, arterial or venous thromboembolic events, PRES, infusion-related reactions, ovarian failure, neutropenia, infection.

Generic Availability:

NO

How Supplied:

Single-dose vial (4mL, 16mL)—1

Pricing for MVASI

16ml of 400mg/16ml vial (Qty: 1)
Appx. price $2690
GoodRx

Colorectal and other GI cancers:

Indications for MVASI:

Metastatic colorectal carcinoma, in combination with 5-FU-based chemotherapy for first- or second-line treatment; or in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based therapy for second-line treatment in patients who have progressed on a first-line bevacizumab-containing regimen.

Limitations of Use:

Not for adjuvant treatment of colon cancer.

Adult:

Give by IV infusion. Infuse 1st dose over 90mins; if tolerated, infuse 2nd dose over 60mins, and subsequent doses over 30mins. 5mg/kg (when used with bolus-IFL) or 10mg/kg (when used with FOLFOX-4) once every 2 weeks until disease progression or unacceptable toxicity; 5mg/kg every 2 weeks or 7.5mg/kg every 3 weeks (when used with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based therapy).

Children:

<18yrs: not established.

Warnings/Precautions:

Do not start therapy before or for at least 28 days after surgery; allow surgical incisions to completely heal (see full labeling). Do not administer if recent history of hemoptysis of ≥ ½-teaspoon of red blood. Discontinue if GI perforations, tracheoesophageal fistula, grade 4 fistula, or fistula formation involving any organ. Discontinue if wound healing complications, Grade 3 or 4 hemorrhage, severe arterial thromboembolic event, grade 4 venous thromboembolic event, hypertensive crisis or encephalopathy, posterior reversible encephalopathy syndrome (PRES), nephrotic syndrome, severe infusion-related reactions, or CHF develops; withhold if severe hypertension or proteinuria ≥2g/24hrs (resume when <2g/24hrs) occurs. History of arterial thromboembolism. Diabetes. Monitor BP every 2–3 weeks. Monitor proteinuria by dipstick urine analysis; if ≥2+, do further assessment with a 24-hour urine collection. Elderly. Increased risk of ovarian failure (premenopausal women). Embryo-fetal toxicity. Advise females of reproductive potential to use effective contraception during and for 6 months after last dose. Pregnancy. Nursing mothers: not recommended (during and for 6 months after last dose).

Pharmacologic Class:

Vascular endothelial growth factor (VEGF) inhibitor.

Interactions:

Increased risk of CHF and decline in LVEF with concomitant anthracycline-based therapy (not indicated use).

Adverse Reactions:

Epistaxis, headache, hypertension, rhinitis, proteinuria, taste alteration, dry skin, rectal hemorrhage, lacrimation disorder, back pain, exfoliative dermatitis; GI perforation and fistulae, wound dehiscence/impaired healing, necrotizing fasciitis (discontinue if occurs), hemorrhage, non-GI fistula formation, arterial or venous thromboembolic events, PRES, infusion-related reactions, ovarian failure, neutropenia, infection.

Generic Availability:

NO

How Supplied:

Single-dose vial (4mL, 16mL)—1

Pricing for MVASI

16ml of 400mg/16ml vial (Qty: 1)
Appx. price $2690
GoodRx

Gynecologic cancers:

Indications for MVASI:

Persistent, recurrent, or metastatic cervical cancer in combination with paclitaxel/cisplatin, or paclitaxel/topotecan.

Adult:

Give by IV infusion. Infuse 1st dose over 90mins; if tolerated, infuse 2nd dose over 60mins, and subsequent doses over 30mins. 15mg/kg every 3 weeks with either paclitaxel/cisplatin, or paclitaxel/topotecan until disease progression or unacceptable toxicity.

Children:

<18yrs: not established.

Warnings/Precautions:

Do not start therapy before or for at least 28 days after surgery; allow surgical incisions to completely heal (see full labeling). Do not administer if recent history of hemoptysis of ≥ ½-teaspoon of red blood. Discontinue if GI perforations, tracheoesophageal fistula, grade 4 fistula, or fistula formation involving any organ. Discontinue if wound healing complications, Grade 3 or 4 hemorrhage, severe arterial thromboembolic event, grade 4 venous thromboembolic event, hypertensive crisis or encephalopathy, posterior reversible encephalopathy syndrome (PRES), nephrotic syndrome, severe infusion-related reactions, or CHF develops; withhold if severe hypertension or proteinuria ≥2g/24hrs (resume when <2g/24hrs) occurs. History of arterial thromboembolism. Diabetes. Monitor BP every 2–3 weeks. Monitor proteinuria by dipstick urine analysis; if ≥2+, do further assessment with a 24-hour urine collection. Elderly. Increased risk of ovarian failure (premenopausal women). Embryo-fetal toxicity. Advise females of reproductive potential to use effective contraception during and for 6 months after last dose. Pregnancy. Nursing mothers: not recommended (during and for 6 months after last dose).

Pharmacologic Class:

Vascular endothelial growth factor (VEGF) inhibitor.

Interactions:

Increased risk of CHF and decline in LVEF with concomitant anthracycline-based therapy (not indicated use).

Adverse Reactions:

Epistaxis, headache, hypertension, rhinitis, proteinuria, taste alteration, dry skin, rectal hemorrhage, lacrimation disorder, back pain, exfoliative dermatitis; GI perforation and fistulae, wound dehiscence/impaired healing, necrotizing fasciitis (discontinue if occurs), hemorrhage, non-GI fistula formation, arterial or venous thromboembolic events, PRES, infusion-related reactions, ovarian failure, neutropenia, infection.

Generic Availability:

NO

How Supplied:

Single-dose vial (4mL, 16mL)—1

Pricing for MVASI

16ml of 400mg/16ml vial (Qty: 1)
Appx. price $2690
GoodRx

Respiratory and thoracic cancers:

Indications for MVASI:

First-line treatment of unresectable, locally advanced, recurrent or metastatic non-squamous, non-small cell lung cancer (NSCLC), in combination with carboplatin and paclitaxel.

Adult:

Give by IV infusion. Infuse 1st dose over 90mins; if tolerated, infuse 2nd dose over 60mins, and subsequent doses over 30mins. 15mg/kg every 3 weeks with carboplatin/paclitaxel until disease progression or unacceptable toxicity.

Children:

<18yrs: not established.

Warnings/Precautions:

Do not start therapy before or for at least 28 days after surgery; allow surgical incisions to completely heal (see full labeling). Do not administer if recent history of hemoptysis of ≥ ½-teaspoon of red blood. Discontinue if GI perforations, tracheoesophageal fistula, grade 4 fistula, or fistula formation involving any organ. Discontinue if wound healing complications, Grade 3 or 4 hemorrhage, severe arterial thromboembolic event, grade 4 venous thromboembolic event, hypertensive crisis or encephalopathy, posterior reversible encephalopathy syndrome (PRES), nephrotic syndrome, severe infusion-related reactions, or CHF develops; withhold if severe hypertension or proteinuria ≥2g/24hrs (resume when <2g/24hrs) occurs. History of arterial thromboembolism. Diabetes. Monitor BP every 2–3 weeks. Monitor proteinuria by dipstick urine analysis; if ≥2+, do further assessment with a 24-hour urine collection. Elderly. Increased risk of ovarian failure (premenopausal women). Embryo-fetal toxicity. Advise females of reproductive potential to use effective contraception during and for 6 months after last dose. Pregnancy. Nursing mothers: not recommended (during and for 6 months after last dose).

Pharmacologic Class:

Vascular endothelial growth factor (VEGF) inhibitor.

Interactions:

Increased risk of CHF and decline in LVEF with concomitant anthracycline-based therapy (not indicated use).

Adverse Reactions:

Epistaxis, headache, hypertension, rhinitis, proteinuria, taste alteration, dry skin, rectal hemorrhage, lacrimation disorder, back pain, exfoliative dermatitis; GI perforation and fistulae, wound dehiscence/impaired healing, necrotizing fasciitis (discontinue if occurs), hemorrhage, non-GI fistula formation, arterial or venous thromboembolic events, PRES, infusion-related reactions, ovarian failure, neutropenia, infection.

Generic Availability:

NO

How Supplied:

Single-dose vial (4mL, 16mL)—1

Pricing for MVASI

16ml of 400mg/16ml vial (Qty: 1)
Appx. price $2690
GoodRx